Abstract
Background
Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage (aSAH) is a common sequelae leading to poorer neurological outcomes and predisposing to various complications.
Methods
A total of 2191 consecutive patients with aSAH were acutely admitted to the Neurointensive Care at the Kuopio University Hospital between 1990 and 2018 from a defined population. A total of 349 (16%) aSAH patients received a ventriculoperitoneal shunt, 101 with an adjustable valve (2012–2018), 232 with a fixed pressure valve (1990–2011), and 16 a valveless shunt (2010–2013). Clinical timelines were reconstructed from the hospital records and nationwide registries until death (n = 120) or June 2019.
Results
Comparing the adjustable valves vs. the fixed pressure valves vs. the valveless shunts, intraventricular hemorrhage was present in 61%, 44% and 100%, respectively. The median times to the shunt were 7 days vs. 38 days vs. 10 days. The rates of the first revision were 25% vs. 32% vs. 69%. The causes included infection in 11% vs. 7% vs. 25% and overdrainage in 1% vs. 4% vs. 31%. The valveless shunt was the only independent risk factor (HR 2.9) for revision. After the first revision, more revisions were required in 48% vs. 52% vs. 45%.
Conclusions
The protocol to shunt evolved over time to favor earlier shunt. In post-aSAH hydrocephalus, adjustable valve shunts, without anti-siphon device, can be installed at an early phase after aSAH, in spite of intraventricular blood, with a modest risk (25%) of revision. Valveless shunts are not recommendable due to high risk of revisions.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is the third most common form of stroke (7 per 100,000)[12] at the lowest median age [21, 31, 35]. Acute aSAH is a complex systemic condition, requiring acute CT diagnosis and neurointensive care [7, 9, 31, 34]. Arterial bleed may cause an intracerebral (ICH) and/or intraventricular hematoma (IVH). Age, clinical condition, ICH, IVH, acute hydrocephalus, and extraventricular drainage (EVD) predict high mortality at 14 days [17], excess mortality at 12 months [19], and subsequent neurological outcome [13, 14, 16, 29].
Chronic hydrocephalus, requiring a permanent shunt, is frequent among aSAH survivors [1, 8, 36]. In our 1551 aSAH patients, six groups were identified with increasing risk (1% to 61%) of shunting [1]. Acute hydrocephalus, with or without IVH, predicted that EVD would be continued by a shunt, especially in case of bacterial infection [1, 10]. Normal ventricular volume on admission (56%) carried a notable risk (8%) of latent shunt [1]. Shunt failures, particularly infection and occlusion, requiring repeated revisions, are still frequent after decades of development [25]. Valveless shunts were suggested to reduce occlusion [2]. Adjustable valves have reduced overdrainage and the need for surgical revision [28]. Concerning shunted aSAH survivors, we found few long-term follow-up studies on shunt revisions [3, 27, 30].
A total of 2191 consecutive aSAH patients were admitted to the Kuopio University Hospital from a defined population (I/1990 to VI/2018). The timelines of the 349 patients with a ventriculoperitoneal shunt were analyzed until death or June 2019. The focus was the 101 patients with an adjustable valve (2012–2018), as compared to the 232 patients with a fixed pressure valve (1990–2011) and the 16 patients with a valveless shunt (2010–2013). The aim was to identify risk factors for the first shunt revision.
Methods
Literature review
PubMed was searched for English articles on humans published between January 2000 and November 2019 using the following terms: [(subarachnoid hemorrhage) OR SAH OR aSAH) AND (shunt* OR shunted OR shunting) AND (revision* OR complication* OR obstruction* OR infection*)]. We searched for the original articles on the aSAH patient cohorts that studied the shunted patients and the revisions of their shunts. Table 1 summarizes the cohorts regarded as relevant for the present study.
Catchment population of Kuopio University Hospital (KUH)
KUH, one of the five University Hospitals in Finland, is an academic, non-profit, publicly funded tertiary center, which has solely provided full-time acute and elective neurosurgical services for the defined KUH catchment population of approximately 850,000 in Eastern Finland. The KUH area contains four Central Hospitals, each with 24/7 neuroacutology, CT services, and intensive care [17]. During the study period from 1990 to 2018, all cases of SAH (CT and spinal tap) were acutely transferred to KUH for neurointensive care, neuroradiology (4-vessel angiography and/or CT angiography), and neurosurgery [17]. Neurointensive care was provided virtually regardless of the age or condition on admission, including H&H 4–5 patients. A dedicated team of neurointensivists, neurosurgeons, and neuroradiologists coordinated the aSAH treatment. KUH Neurovascular Group evacuated significant ICHs with immediate microsurgery. The KUH aSAH protocol followed international recommendations in detail [7, 9, 31, 34], including routine extraventricular drainage (EVD) and parenchymal ICP monitoring, decompressive craniectomy (DC) when needed, and intra-arterial nimodipine in delayed brain ischemia.
Kuopio Intracranial Aneurysm (IA) Patient and Family Database
The database, prospective since 1995, contains all cases of unruptured and ruptured IAs admitted to KUH since 1980. A dedicated, full-time nurse administrates the database; interviews all new IA patients, including their family history; and arranges the follow-ups. The clinical data, including prescribed medicines, hospital diagnosis, and causes of death, have been fused from the national registries, using the Finnish personal codes. We have previously characterized the aSAH patients, e.g., diabetes mellitus [24], hypertension [23], for the 14-day mortality and organ donation [17], 12-month mortality [15], shunt-dependent hydrocephalus [1], epilepsy [14], psychosis [13], and long-term excess mortality [16]. Three 1-degree relatives with a diagnosed sIA disease form an sIA family.
Study population
A total of 2191 consecutive adult (> 18 years) aSAH patients were acutely admitted to the KUH Neurointensive Care from 1990 to 2018 from a defined population (Fig. 1). Their clinical lifelines have been reconstructed from their clinical data in the Kuopio database and from the national clinical registries until death or the last follow-up [13, 29]. The final study population consisted 349 aSAH patients who received their first ventriculoperitoneal shunt in a median time of 24 days (IQR 9–60 days) after aSAH (Fig. 1, Table 2).
Variables and clinical data retrieval sources
The characteristics and variables of the patients (n = 349) and the primary shunts are described in Table 2. The clinical data was retrieved and reviewed from the following sources: Kuopio IA Database, with data fusion from the national registries; KUH case reports, referrals from the four Central Hospitals, and neurosurgical operative reports on shunt installations and revisions (manually 1990–2004; digitally until June 2019); neuroimaging (manually 1990–2002; digitally until June 2019); monitoring data before, during, and after all shunt installations and revisions; and laboratory and bacteriology data. The follow-up time ended at death (n = 120) or June 2019. No patients were lost to follow-up.
Shunt surgery and follow-up for shunt complications
In the KUH catchment population, all adult shunt installations and revisions have been performed by KUH Neurosurgery. The shunted patients have been followed by the KUH Neurosurgery and Neurology Departments of the four Central Hospitals. During the study period since 1990, all Hospitals have had 24/7 CT services. Since 2010, adjustable valves have been reset also in the Central Hospitals. KUH Neurosurgery have treated all shunt complications, e.g., occlusions, infections, intracranial hematomas, overdrainages (clinical and/or radiological signs leading to valve adjustment or shunt revision), and subdural effusions.
Types of shunt valves used in 349 aSAH patients
During the recruitment period from 1990 to 2018, three types of valves were used (Table 2, Fig. 1). The adjustable valves without anti-siphon device enabled us to insert shunts earlier thus reducing the time of EVD.
-
1.
Fixed pressure valves (n = 232):
-
Exclusively from 1990 to 2009 (n = 198); occasionally from 2010 to 2017 (n = 34)
-
> 5 mmHg opening pressure (n = 196)
-
0–5 mmHg opening pressure (n = 36)
-
-
2.
Adjustable valves (n = 101):
-
Used since 2010 and the main valve type since 2012.
-
Medtronic Strata NSC without an anti-siphon device (n = 86) or Medtronic Strata II (n = 15). Valve without anti-siphon device was used to reduce the risk for obstruction due to blood in CSF.
-
Control head CT (n = 97) in a median of 3 days (IQR 2–6), MRI (n = 3), or skull x-ray (n = 1) to verify the ventricular catheter position after the shunt installation.
-
-
3.
Valveless primary shunts in the study were Codman Uni-Shunts (n = 16); these were inserted between 2010 and 2013.
Antibiotic prophylaxis (cefuroxime) was routinely administered i.v. (i) during the EVD and shunt installations (1.5 g) and (ii) administered i.v. 1.5 g three times a day during the EVD period.
Statistical analysis
Continuous variables were reported as medians and interquartile ranges (IQR). Frequencies and percentages were used with the categorical and the dichotomous variables. The association of the continuous variables on the first shunt revision was analyzed with the Mann–Whitney U test or the Kruskal–Wallis test. Categorical variables were evaluated by the χ2 test. The Cox regression analysis was used to identify the independent risk factors for the first shunt revision. Statistical analysis was performed using SPSS version 25.0 (SPSS, Inc., Chicago, IL). The differences were statistically significant if the p-value was < 0.05.
Ethical approvals
The study was approved by the Ethical Committee of the Kuopio University Hospital. This was a retrospective database study including only the patients already treated in KUH for aSAH. The need for additional consent for this registry study was waived by the Ethics Committee of KUH. The data integration from the national registries was performed with the approval of the Ministry of Social Affairs and Health of Finland and the National Institute for Health and Welfare.
Results
The study population consisted of 349 aSAH patients who received their first ventriculoperitoneal shunt from 1990 to 2018 with three almost consecutive valve types after aSAH (Fig. 1, Table 2). Of the 349 patients, 111 (32%) underwent the first shunt revision in median of 23 days (IQR 6–111) until death (n = 124) or June 2019, a total of 2513 follow-up years and a median of 8.3 years (Fig. 2).
Overall risk of shunt revision
The risk for the first revision was equal for the 101 adjustable valve shunts and the 196 fixed medium-pressure valve shunts but significantly lower (p = 0.01) than for the 16 valveless shunts (Table 2, Fig. 2). In multivariate Cox regression analysis, the valveless shunt was the only independent risk factor (HR 2.9), with age group ≤ 57 years, EVD, and fixed low-pressure valve showing no significance (Table 3). Hunt and Hess grade, antibiotic-impregnated catheters, ICH, and IVH were tested but did not have statistical significance in the multivariate analysis.
Adjustable valves (n = 101; 2012–2018)
Of the 349 shunted patients, 101 had an adjustable valve (Table 2, Fig. 3). Figure 4 presents a representative CT slice of each patient before the shunt insertion, with a special emphasis on the intraventricular blood amount. The puncture sites were frontal (n = 94) or occipital (n = 7).
Antibiotic-impregnated shunt was used in 65 patients and silver-impregnated ventricular catheter with antibiotic-impregnated distal catheter in 21 patients (Table 4).
The initial valve settings were either 1.5 T (n = 78), 1.0 T (n = 19), 0.5 T (n = 2), or 2.0 T (n = 2). One or more adjustments were required in 32 (32%) of the 101 patients, due to clinical overdrainage in 17 (17%) in median of 71 days (IQR 6–129) and clinical underdrainage in 15 (15%) in a median of 4 days (IQR 3–14).
Of the 101 patients, 82 (81%) had EVD and 19 (19%) had not (Fig. 3). The median time to shunt insertion was 7 days (IQR 5–11) with EVD (acute hydrocephalus) and 34 days (IQR 14–48) without EVD (latent hydrocephalus). The median follow-up time since shunt insertion, until death (n = 15) or June 2019, was 47 months (IQR 25–66).
No shunt revision was required in 76 (75%) of the 101 patients, until death (n = 10) or June 2019, a median revision-free time of 47 months. Of these 76 patients though, 23 (30%) required adjustments of the valve settings, at least once. In overall, 53 (52%) of the 101 patients, with a median time of 8 days to shunt insertion, did not require any shunt revisions or adjustments (Fig. 3).
Shunt revision was required in 25 (25%) of the 101 patients, until death (n = 5) or June 2019, in a median time of 7 days since shunt insertion (Table 4, Fig. 3). The cumulative rate for the first revision was 14% at 1 month and 23% at 1 year (Fig. 2). Of the 25 patients with shunt revision, nine had previous valve adjustments. In overall, multiple (two or more) revisions were required in 12 (48%) of the 25 revised patients.
Shunt infection (n = 11) was the most common cause for shunt revision, in a median of 5 days (Table 4, Fig. 3). All 11 patients had EVD and i.v. cefuroxime prophylaxis since the shunt installation. Ten patients had clinical meningitis, including decreased CSF glucose, and one had a wound infection. However, bacterial cultures remained negative, except in two cases (Staphylococcus warneri and Staphylococcus aureus) considered possible contaminations. The PCR testing of CSF samples was not performed. The infections somewhat clustered in the early shunts (Fig. 3).
Valve occlusion (n = 8) was the second most common reason for shunt revision, in a median of 12 days (Table 4, Fig. 3). The 15 shunts with the anti-siphon device were installed in a median of 39 days (IQR 8–220), and only one of them occluded. The 86 shunts without the anti-siphon device were installed much earlier (see Methods), in a median of 7 days (IQR 5–11), and seven of them occluded.
Valveless shunts (n = 16; 2010–2013)
Of the 349 shunted patients, 16 (4.6%) had a valveless shunt in a median of 10 days after aSAH (Table 2, Table 4, Fig. 1). All 16 patients had EVD. The median follow-up time since shunt insertion, until death (n = 4) or June 2019, was 90 months (19–106).
No shunt revision was required in five (31%) patients, until death (n = 3) or June 2019, a median revision-free time of 72 months. Shunt revision was required in 11 (69%) patients, until death (n = 1) or June 2019, in a median of 17 days (Table 4, Fig. 2). The causes of revision were shunt overdrainage (n = 5), shunt infection (n = 4), and ventricular catheter occlusion (n = 2) (Table 4). In overall, multiple revisions were required in 5 (45%) of the 11 revised patients.
Fixed pressure valves (n = 232; 1990–2011)
Of the 349 shunted patients, 232 (66%) had a fixed pressure valve, 36 with a low-pressure valve (0–5 mmHg), and 196 with a medium-pressure valve (> 5 mmHg). Of the 232 patients, 156 (67%) had EVD and 76 (33%) had not. The median time to shunt insertion was 35 days (IQR 16–86) with EVD (acute hydrocephalus) and 48 days (IQR 24–100) without EVD (latent hydrocephalus). The median follow-up time since shunt insertion, until death (n = 105) or June 2019, was 133 months (91–227).
No shunt revision was required in 157 (68%) patients, until death (n = 72) or June 2019, a median revision-free time of 146 months (Table 2). Shunt revision was required in 75 (32%) patients, until death (n = 33) or June 2019, in a median of 48 days (Table 2, Fig. 2). The two most common causes of revision were valve occlusion (n = 27) and shunt infection (n = 16), reversal as compared to adjustable valves (Table 4). In overall, multiple revisions were required in 39 (52%) of the 75 revised patients.
Risk of revision with adjustable valve, fixed pressure valve, and valveless shunts
As Table 3 and Fig. 2 indicate, the risk for the first revision was equal for the 101 adjustable valve shunts and the 196 fixed medium-pressure valve shunts but significantly lower (p = 0.01) than for the 16 valveless shunts.
Discussion
In our basic cohort of 2191 consecutive aSAH patients from a defined population (1990–2018), a total of 349 (17%) required a permanent ventriculoperitoneal shunt due to acute or latent hydrocephalus. In two previous large cohorts, the shunt dependency was 13% and 19% (Table 1) in 888 and 3120 aSAH patients, respectively [27, 30]. Shunt failures in hydrocephalus of various causes, including aSAH, which may require repeated revisions, are frequent after 40 decades of development [25].
Shunt failures may be (i) mechanical (catheter disinsertion; catheter disconnection; exposure to skin), (ii) biological (meningitis; infection of the shunt; occlusion of catheters or valves), or (iii) hydrodynamic (underdrainage; overdrainage). We found few large long-term follow-up studies on the shunt revisions in post-aSAH hydrocephalus [3, 27, 30].
In the present study of 349 shunted patients, the clinical date point timelines, reconstructed with the personal identity codes from the Finnish nationwide clinical registries, were analyzed until death (n = 124) or June 2019 with none lost to follow-up. A total of 111 (32%) patients underwent at least one shunt revision. In multivariate analysis, no other independent risk factors for the shunt revision than the use of valveless shunt were found. The focus was the 101 patients with an adjustable valve (2012–2018), as compared to the 232 patients with a fixed pressure valve (1990–2011) and the 16 patients with a valveless shunt (2010–2013) (Fig. 1).
In the 101 aSAH patients with an adjustable valve, the median time from the admission to the shunt was 7 days (Figs. 3and 4). No shunt revision was required in 75%, a median revision-free time of 47 months. In 32 patients, the valve settings had to be adjusted after the shunt, and nine of them required a surgical shunt revision. In overall, shunt revision was required in 25% in a median of 7 days. The most common causes were shunt infection (11%) in a median of 5 days, in spite of intraoperative cefuroxime prophylaxis, and shunt occlusion (8%) in a median of 12 days. In the historic fixed pressure valve group (Fig. 1), the shunts were installed (median 38 days) and revised (median 48 days) significantly later, at an almost equal rate though (Fig. 2). In two previous aSAH cohorts, the adjustable valve shunts were less often revised as compared to the fixed pressure valve shunts: 7% and 9% vs. 22% and 30%, respectively [22, 28].
The adjustable valves, in our hands without the anti-siphon device, brought an important paradigm shift in our service as compared to the period of fixed pressure valves. Shunt valves without anti-siphon device enabled us to install shunts earlier to minimize the risk of occlusion and to reduce the time of EVD. Early shunt excludes the possibility to use EVD in maintaining an adequate CPP in case of severe vasospasm. However, early shunt was considered as soon as ICP monitoring was not required due to the decreased level of consciousness, but patients were still requiring CSF drainage. Early shunt can also shorten the neurointensive care period and can lead to earlier mobilization. Prolonged EVD or spinal drainage are risk factors for meningitis, even with antibiotic prophylaxis and use of antibiotic-impregnated catheters [10]. We can speculate that due to the use of antibiotic-impregnated catheters, the shunt infection rate was not increased despite of earlier shunt insertion. Two previous studies also supported early conversion of EVD into a ventriculoperitoneal shunt [18, 32]. Finally, adjustable valve shunts resolved the problems of overdrainage and underdrainage, previously requiring surgical revisions. This tallies with a recent study comparing 173 fixed pressure valves and 16 adjustable valves [6].
In our study, 16 primary valveless shunts were inserted in a brief 4-year period (Fig. 1), with the idea that shunting could take place at an earlier phase and with more blood in the CSF. However, the valveless shunts in our hands proved unsatisfactory: as many as 11 (69%) required at least one revision, five (31%) of them for overdrainage (Fig. 2). In contrast, in the Danish population-based cohort of 214 post-hemorrhagic hydrocephalus patients, including 161 SAH patients, there was no significant difference in the revision rates between the 137 valveless (26%) and 77 valve-regulated (29%) ventriculoperitoneal shunts [2]. Instead, the rate of overdrainage was significantly higher with the valveless shunts: 40% vs. 9%. In our overall series, the rates of overdrainage were 1%, 4%, and 31% for the 101 adjustable valve, 232 fixed pressure valve, and 16 valveless ventriculoperitoneal shunts, respectively. Our findings emphasize the need for clinical trials and prospective quality registries when implementing new innovations in neurosurgery.
The strengths of the present study are derived from the free tax-paid Finnish health care system. The five university hospitals of Finland have their own catchment areas which supports disease cohorts with minimal selection and long-term follow-ups with almost none dropped. Using the Finnish identity codes, all contacts to the healthcare system are automatically archived in the national clinical registries. Our follow-up was considerably longer as compared to previous studies (Table 1).
All shunt insertions and revisions were performed by the KUH neurosurgeons. There are also limitations. Our study is retrospective, although the database prospectively collected all aSAH patients through the study period. Furthermore, the detailed neurointensive care monitoring data, digitally available in the Finnish nationwide database [31], was not utilized here. Such data would be important for more detailed prediction of shunt occlusions, infections, and revisions in post-aSAH hydrocephalus.
The mechanisms, such as neuroinflammation, behind acute, latent, and chronic post-aSAH hydrocephalus are not fully understood, e.g., possible alterations in ependymal cells, ciliary beat, arachnoid villi, CSF production and resorption, or glymphatic circulation [11, 20]. Considering neuroinflammation, the use of dexamethasone after aSAH has been associated with the reduction in unfavorable outcome and the incidence of hydrocephalus [5, 26, 33]. The impact of dexamethasone, or any other modulator of inflammation, on the revision rates in shunted aSAH has not been established. Individual factors, including advanced age, concomitant diseases, and long neurointensive care, may affect the individual predisposition or resilience to shunt occlusions or infections — and might be modifiable.
Risk factors of shunt occlusion or shunt infection are difficult to define. There is no standard diagnosis for shunt infection, and different guidelines are used [37]. Negative CSF or catheter culture does not totally rule out shunt infection, especially under antibiotic prophylaxis, such as cefuroxime during our early conversions of EVD to shunts. Furthermore, asymptomatic infection may cause shunt occlusion. For further research, it is important to use PCR or sequencing of CSF, catheters, and valve contents to identify the causative pathogen or pathogens in all cases of occluded or infected shunt material.
Long-term outcome and quality of life of shunted aSAH survivors require further research. Risk factors of repeated revisions and possible methods to prevent them should be investigated. In our study, 12 (12%) of the 101 adjustable valve shunt patients and 39 (17%) of the 232 fixed pressure valves underwent two or more revisions. Among the 585 patients with a ventriculoperitoneal shunt for post-aSAH hydrocephalus, 74 (13%) underwent two or more revisions (32 at least three; 21 at least four) [27]. O’Kelly et al. [27] were unable to glean risk factors for the multiple shunt revisions. Finally, it is not known whether shunt-dependent hydrocephalus after aSAH is an independently dementing brain condition, apart from brain injuries at the acute and subacute phase [4].
Conclusions
Our analysis of 349 patients with a ventriculoperitoneal shunt for hydrocephalus due to aneurysmal subarachnoid hemorrhage (aSAH) suggests the following:
-
1. The protocol to shunt evolved over time to favor earlier shunt instead of weaning.
-
2. Adjustable valve shunts, in our hands without the anti-siphon device, can be installed at an early phase after aSAH with a modest risk (25%) of shunt revision.
-
3. Valveless shunts are not recommendable due to significantly higher risk of revision as compared to shunts with adjustable opening pressure.
References
Adams H, Ban VS, Leinonen V, Aoun SG, Huttunen J, Saavalainen T, Lindgren A, Frosen J, Fraunberg M, Koivisto T, Hernesniemi J, Welch BG, Jaaskelainen JE, Huttunen TJ (2016) Risk of Shunting After Aneurysmal Subarachnoid Hemorrhage: A Collaborative Study and Initiation of a Consortium. Stroke 47:2488–2496
Andreasen TH, Holst AV, Lilja A, Andresen M, Bartek J Jr, Eskesen V, Juhler M (2016) Valved or valveless ventriculoperitoneal shunting in the treatment of post-haemorrhagic hydrocephalus: a population-based consecutive cohort study. Acta Neurochir (Wien) 158:261–70 discussion 270
Chalouhi N, Whiting A, Anderson EC, Witte S, Zanaty M, Tjoumakaris S, Gonzalez LF, Hasan D, Starke RM, Hann S, Ghobrial GM, Rosenwasser R, Jabbour P (2014) Comparison of techniques for ventriculoperitoneal shunting in 523 patients with subarachnoid hemorrhage. J Neurosurg 121:904–907
Corraini P, Henderson VW, Ording AG, Pedersen L, Horváth-Puhó E, Sørensen HT (2017) Long-term risk of dementia among survivors of ischemic or hemorrhagic stroke. Stroke 48:180–186
Czorlich P, Sauvigny T, Ricklefs F, Abboud T, Nierhaus A, Vettorazzi E, Reuter DA, Regelsberger J, Westphal M, Schmidt NO (2017) Impact of dexamethasone in patients with aneurysmal subarachnoid haemorrhage. Eur J Neurol 24:645–651
Darkwah Oppong M, Droste L, Pierscianek D, Wrede KH, Rauschenbach L, Dammann P, Herten A, Forsting M, Sure U, Jabbarli R (2020) Adjustable pressure valves for chronic hydrocephalus following subarachnoid hemorrhage: is it worthwhile? Clin Neurol Neurosurg 198:106133
de Oliveira Manoel AL, van der Jagt M, Amin-Hanjani S, Bambakidis NC, Brophy GM, Bulsara K, Claassen J, Connolly ES, Hoffer SA, Hoh BL, Holloway RG, Kelly AG, Mayer SA, Nakaji P, Rabinstein AA, Vajkoczy P, Vergouwen MDI, Woo H, Zipfel GJ, Suarez JI, Unruptured Aneurysms and SAH - CDE Project Investigators (2019) Common data elements for unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage: recommendations from the working group on hospital course and acute therapies-proposal of a multidisciplinary research group. Neurocrit Care 30:36–45
Diesing D, Wolf S, Sommerfeld J, Sarrafzadeh A, Vajkoczy P, Dengler NF (2018) A novel score to predict shunt dependency after aneurysmal subarachnoid hemorrhage. J Neurosurg 128:1273–1279
Diringer MN, Bleck TP, 3rd Claude Hemphill J, Menon D, Shutter L, Vespa P, Bruder N, Jr Connolly ES, Citerio G, Gress D, Hanggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng MY, Vergouwen MD, Wolf S, Zipfel G, Neurocritical Care Society (2011) Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care 15:211–240
Dorresteijn KRIS, Brouwer MC, Jellema K, van de Beek D (2020) Bacterial external ventricular catheter-associated infection. Expert Rev Anti Infect Ther 18:219–229
Fam MD, Zeineddine HA, Eliyas JK, Stadnik A, Jesselson M, McBee N, Lane K, Cao Y, Wu M, Zhang L, Thompson RE, John S, Ziai W, Hanley DF, Awad IA, Trial Investigators CLEARIII (2017) CSF inflammatory response after intraventricular hemorrhage. Neurology 89:1553–1560
Hughes JD, Bond KM, Mekary RA, Dewan MC, Rattani A, Baticulon R, Kato Y, Azevedo-Filho H, Morcos JJ, Park KB (2018) Estimating the global incidence of aneurysmal subarachnoid hemorrhage: a systematic review for central nervous system vascular lesions and meta-analysis of ruptured aneurysms. World Neurosurg 115:430-447.e7
Huttunen J, Lindgren A, Kurki MI, Huttunen T, Frosen J, von Und Zu, Fraunberg M, Koivisto T, Kalviainen R, Raikkonen K, Viinamaki H, Jaaskelainen JE, Immonen A (2016) Antidepressant use after aneurysmal subarachnoid hemorrhage: a population-based case-control study. Stroke 47:2242–2248
Huttunen JM, Kurki MI, von und zu Fraunberg M, Koivisto T, Ronkainen A, Rinne J, Jaaskelainen JE, Kalviainen R, Immonen A, (2015) Epilepsy after aneurysmal subarachnoid hemorrhage: a population-based, long-term follow-up study. Neurology 85:1997
Huttunen T , von und zuFraunberg M, Frosen J, Lehecka M, Tromp G, Helin K, Koivisto T, Rinne J, Ronkainen A, Hernesniemi J, Jaaskelainen JE (2010) Saccular intracranial aneurysm disease: distribution of site, size, and age suggests different etiologies for aneurysm formation and rupture in 316 familial and 1454 sporadic eastern Finnish patients. Neurosurgery 66:631–8 discussion 638
Huttunen T, von und ZuFraunberg M, Koivisto T, Ronkainen A, Rinne J, Sankila R, Seppa K, Jaaskelainen JE (2011) Long-term excess mortality of 244 familial and 1502 sporadic one-year survivors of aneurysmal subarachnoid hemorrhage compared with a matched Eastern Finnish catchment population. Neurosurgery 68:20–27
Kämäräinen OP, Huttunen J, Lindgren A, Lång M, Bendel S, Uusaro A, Parviainen I, Koivisto T, Isoniemi H, Jääskeläinen JE (2018) Identification of potential organ donors after aneurysmal subarachnoid hemorrhage in a population-based neurointensive care in Eastern Finland. Acta Neurochir (Wien) 160:1507–1514
Kang DH , Park J, Park SH, Kim YS, Hwang SK, Hamm IS (2010) Early ventriculoperitoneal shunt placement after severe aneurysmal subarachnoid hemorrhage: role of intraventricular hemorrhage and shunt function. Neurosurgery 66:904–8 discussion 908–9
Karamanakos PN, von Und Zu, Fraunberg M, Bendel S, Huttunen T, Kurki M, Hernesniemi J, Ronkainen A, Rinne J, Jaaskelainen JE, Koivisto T (2012) Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 78:631–639
Karimy JK, Reeves BC, Damisah E, Duy PQ, Antwi P, David W, Wang K, Schiff SJ, Limbrick DD Jr, Alper SL, Warf BC, Nedergaard M, Simard JM, Kahle KT (2020) Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets. Nat Rev Neurol 16:285–296
Korja M, Lehto H, Juvela S, Kaprio J (2016) Incidence of subarachnoid hemorrhage is decreasing together with decreasing smoking rates. Neurology 87:1118–1123
Lee JK, Seok JY, Lee JH, Choi EH, Phi JH, Kim SK, Wang KC, Lee HJ (2012) Incidence and risk factors of ventriculoperitoneal shunt infections in children: a study of 333 consecutive shunts in 6 years. J Korean Med Sci 27:1563–1568
Lindgren AE, Kurki MI, Riihinen A, Koivisto T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainenvon und zuFraunberg JEM (2014) Hypertension predisposes to the formation of saccular intracranial aneurysms in 467 unruptured and 1053 ruptured patients in Eastern Finland. Ann Med 46:169–176
Lindgren AE, Kurki MI, Riihinen A, Koivisto T, Ronkainen A, Rinne J, Hernesniemi J, Eriksson JG, Jaaskelainen JE, von und zuFraunberg M (2013) Type 2 diabetes and risk of rupture of saccular intracranial aneurysm in eastern Finland. Diabetes Care 36:2020–2026
Merkler AE, Ch’ang J, Parker WE, Murthy SB, Kamel H (2017) The rate of complications after ventriculoperitoneal shunt surgery. World Neurosurg 98:654–658
Mohney N, Williamson CA, Rothman E, Ball R, Sheehan KM, Pandey AS, Fletcher JJ, Jacobs TL, Thompson BG, Rajajee V (2018) A propensity score analysis of the impact of dexamethasone use on delayed cerebral ischemia and poor functional outcomes after subarachnoid hemorrhage. World Neurosurg 109:e655–e661
O’Kelly CJ, Kulkarni AV, Austin PC, Urbach D, Wallace MC (2009) Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: incidence, predictors, and revision rates. Clinical article J Neurosurg 111:1029–1035
Orrego-González E, Enriquez-Marulanda A, Ascanio LC, Jordan N, Hanafy KA, Moore JM, Ogilvy CS, Thomas AJ (2020) A cohort comparison analysis of fixed pressure ventriculoperitoneal shunt valves with programmable valves for hydrocephalus following nontraumatic subarachnoid hemorrhage. Oper Neurosurg (Hagerstown) 18:374–383
Paavola JT, Vantti N, Junkkari A, Huttunen TJ, von Und Zu, Fraunberg M, Koivisto T, Kamarainen OP, Lang M, Meretoja A, Raikkonen K, Viinamaki H, Jaaskelainen JE, Huttunen J, Lindgren AE (2019) Antipsychotic use among 1144 patients after aneurysmal subarachnoid hemorrhage. Stroke 50:1711–1718
Paisan GM, Ding D, Starke RM, Crowley RW, Liu KC (2018) Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: predictors and long-term functional outcomes. Neurosurgery 83:393–402
Raj R , Bendel S, Reinikainen M, Hoppu S, Laitio R, Ala-Kokko T, Curtze S, Skrifvars MB (2018) Costs, outcome and cost-effectiveness of neurocritical care: a multi-center observational study. Crit Care 22:225–018–2151–5
Rammos S, Klopfenstein J, Augspurger L, Wang H, Wagenbach A, Poston J, Lanzino G (2008) Conversion of external ventricular drains to ventriculoperitoneal shunts after aneurysmal subarachnoid hemorrhage: effects of site and protein/red blood cell counts on shunt infection and malfunction. J Neurosurg 109:1001–1004
Schürkämper M, Medele R, Zausinger S, Schmid-Elsaesser R, Steiger HJ (2004) Dexamethasone in the treatment of subarachnoid hemorrhage revisited: a comparative analysis of the effect of the total dose on complications and outcome. J Clin Neurosci 11:20–24
Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, Organization ES (2013) European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 35:93–112
van Gijn J, Kerr RS, Rinkel GJ (2007) Subarachnoid haemorrhage. Lancet 369:306–318
Wilson CD, Safavi-Abbasi S, Sun H, Kalani MY, Zhao YD, Levitt MR, Hanel RA, Sauvageau E, Mapstone TB, Albuquerque FC, McDougall CG, Nakaji P, Spetzler RF (2017) Meta-analysis and systematic review of risk factors for shunt dependency after aneurysmal subarachnoid hemorrhage. J Neurosurg 126:586–595
Zervos T, Walters BC (2019) Diagnosis of ventricular shunt infection in children: a systematic review. World Neurosurg 129:34–44
Funding
Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital. The study was funded by the Maire Taponen Foundation, Pro Humanitate Foundation, the Päivikki and Sakari Sohlberg Foundation, the Kuopio University Hospital, and the Academy of Finland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Vascular Neurosurgery - Aneurysm
Joona Tervonen and Hadie Adams are first equal authorship
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tervonen, J., Adams, H., Lindgren, A. et al. Shunt performance in 349 patients with hydrocephalus after aneurysmal subarachnoid hemorrhage. Acta Neurochir 163, 2703–2714 (2021). https://doi.org/10.1007/s00701-021-04877-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00701-021-04877-1